Form 4: OnKure Therapeutics Director Receives Stock Option Grant

Director Andrew John Phillips was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard compensation.

Summary

• Director Andrew John Phillips acquired 7,650 stock options in OnKure Therapeutics, Inc. (OKUR).
• The options have an exercise price of $4.30 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The vesting of these options is contingent upon the director continuing as a service provider through the vesting date.

Future Outlook

The options vest on the earlier of June 4, 2027, or the day prior to the issuer's next annual meeting of stockholders, provided the director remains a service provider.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Trading, Stock Options, Director Compensation